^
    CCND1 expression
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    CD79B mutation
    Diffuse Large B Cell Lymphoma
    rituximab + zanubrutinib
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    CD79A mutation
    Diffuse Large B Cell Lymphoma
    zanubrutinib
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    CD79A mutation
    Diffuse Large B Cell Lymphoma
    rituximab + zanubrutinib
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    AP2M1 overexpression
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    BCL2 positive + LGALS3 expression
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive: A1 - Approval
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive: A1 - Approval
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Ruxience (rituximab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab + polatuzumab vedotin
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    lenalidomide + tafasitamab
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    loncastuximab tesirine
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    selinexor
    Sensitive: A1 - Approval
    No biomarker
    Mediastinal B Cell Lymphoma
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Mediastinal B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab / hyaluronidase
    Sensitive: A1 - Approval
    CD20 positive
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: A1 - Approval
    No biomarker
    Diffuse Large B Cell Lymphoma
    polatuzumab vedotin
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    brentuximab vedotin
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab + lenalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    lenalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Mediastinal B Cell Lymphoma
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    ibrutinib
    Sensitive: A2 - Guideline
    TNFRSF8 positive
    Diffuse Large B Cell Lymphoma
    brentuximab vedotin
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    MINE
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-GemOx
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    GemOx
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    ESHAP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    ICE
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    RICE
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    carboplatin + rituximab + gemcitabine + dexamethasone
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    carboplatin + gemcitabine + dexamethasone
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    GDP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    RGDP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    DHAX
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    DHAP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-DHAP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    EPOCH-R
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    CEOP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    CEPP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-ESHAP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-GCVP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-CEOP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-CEPP
    Sensitive: A2 - Guideline
    No biomarker
    Diffuse Large B Cell Lymphoma
    R-CDOP
    Sensitive: A2 - Guideline
    MYC rearrangement + BCL6 rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A2 - Guideline
    MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A2 - Guideline
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A2 - Guideline
    MYC overexpression + BCL2 overexpression
    Diffuse Large B Cell Lymphoma
    ibrutinib
    Sensitive: B - Late Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    MYC rearrangement
    Diffuse Large B Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    LDH elevation
    Diffuse Large B Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    No biomarker
    Diffuse Large B Cell Lymphoma
    ALLO-501A
    Sensitive: B - Late Trials
    No biomarker
    Diffuse Large B Cell Lymphoma
    EZM0414
    Sensitive: B - Late Trials
    No biomarker
    Diffuse Large B Cell Lymphoma
    FT516
    Sensitive: B - Late Trials
    EZH2 mutation
    Diffuse Large B Cell Lymphoma
    tazemetostat
    Sensitive: C1 - Off-label
    BCL2 expression
    Diffuse Large B Cell Lymphoma
    venetoclax + obinutuzumab
    Sensitive: C2 – Inclusion Criteria
    CD79B mutation
    Diffuse Large B Cell Lymphoma
    ibrutinib
    Sensitive: C2 – Inclusion Criteria
    MYC expression
    Diffuse Large B Cell Lymphoma
    RG6146
    Sensitive: C2 – Inclusion Criteria
    BIRC5 expression
    Diffuse Large B Cell Lymphoma
    pembrolizumab + MVP-S
    Sensitive: C2 – Inclusion Criteria
    MYC rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: C2 – Inclusion Criteria
    BCL6 rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: C2 – Inclusion Criteria
    CD20 positive
    Diffuse Large B Cell Lymphoma
    GEN3013
    Sensitive: C2 – Inclusion Criteria
    CD79B mutation
    Diffuse Large B Cell Lymphoma
    zanubrutinib
    Sensitive: C2 – Inclusion Criteria
    BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: C2 – Inclusion Criteria
    NOTCH1 mutation
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive: C2 – Inclusion Criteria
    TP53 mutation
    Diffuse Large B Cell Lymphoma
    rituximab
    Resistant: C2 – Inclusion Criteria
    CD79B mutation
    Diffuse Large B Cell Lymphoma
    zanubrutinib
    Sensitive: C2 – Inclusion Criteria
    MYC overexpression
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Resistant: C3 – Early Trials
    MYC negative
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive: C3 – Early Trials
    MYC positive
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive: C3 – Early Trials
    MAD2L2 overexpression
    Diffuse Large B Cell Lymphoma
    rituximab
    Resistant: C3 – Early Trials
    CRTAM overexpression
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    BTLA overexpression
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    LEF1 overexpression
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    KLHL14 mutation
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    LRP1B mutation
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    PD-L1 overexpression
    Diffuse Large B Cell Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    BCL2 positive
    Diffuse Large B Cell Lymphoma
    methotrexate
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    cytarabine + methotrexate
    Resistant: C3 – Early Trials
    BCL2 expression + MYC expression
    Diffuse Large B Cell Lymphoma
    methotrexate
    Resistant: C3 – Early Trials
    BCL2 expression + MYC expression
    Diffuse Large B Cell Lymphoma
    cytarabine + methotrexate
    Resistant: C3 – Early Trials
    BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    EPOCH-R
    Sensitive: C3 – Early Trials
    LDH elevation
    Diffuse Large B Cell Lymphoma
    ViPOR
    Sensitive: C3 – Early Trials
    BCL6 translocation
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    BCL2 expression + MYC expression
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    MYC translocation + BCL2 translocation
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    MYC translocation + BCL6 translocation
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    MYC positive + BCL2 positive
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: C3 – Early Trials
    MYC positive + BCL2 positive + BCL6 positive
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive: C3 – Early Trials
    BCL2 amplification
    Diffuse Large B Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    BCL2 positive
    Diffuse Large B Cell Lymphoma
    venetoclax
    Sensitive: C3 – Early Trials